Future oncologyPub Date : 2025-02-01Epub Date: 2025-01-09DOI: 10.1080/14796694.2024.2434388
Shanu Modi
{"title":"Trastuzumab deruxtecan in previously treated HER2-low advanced breast cancer: a plain language summary of the DESTINY-Breast04 study.","authors":"Shanu Modi","doi":"10.1080/14796694.2024.2434388","DOIUrl":"10.1080/14796694.2024.2434388","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"367-380"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11813202/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947378","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2025-01-09DOI: 10.1080/14796694.2024.2442295
Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis Nikolaou, Zoe Paparepa, Foteini Papageorgiou, Konstantinos N Syrigos
{"title":"Real-world treatment patterns in patients with non-metastatic non-small cell lung cancer in Greece: the 'EVIDENCE' study.","authors":"Giannis Mountzios, Sofia Lampaki, Helena Linardou, Vassilis Georgoulias, Dimitrios Mavroudis, Stavros Anevlavis, Andriani Charpidou, Maria Lykka, Dionysis Spyratos, Evangelos G Sarris, Alvertos Somarakis, Christina Papista, Alexandros Glentis, Aristeidis Nikolaou, Zoe Paparepa, Foteini Papageorgiou, Konstantinos N Syrigos","doi":"10.1080/14796694.2024.2442295","DOIUrl":"10.1080/14796694.2024.2442295","url":null,"abstract":"<p><strong>Background: </strong>The treatment landscape of non-metastatic non-small cell lung cancer (NM-NSCLC) is rapidly evolving with recent approvals of immunotherapies and targeted therapies.</p><p><strong>Methods: </strong>This retrospective study included 202 adults diagnosed with NM-NSCLC between 1 January 2018 and 31 December 2020 primarily aiming to capture initial management strategies.</p><p><strong>Results: </strong>Most frequent treatment patterns among Stage I/II patients (<i>N</i> = 84) were surgery only (48.8%) and surgery with adjuvant chemotherapy (with/without RT; 42.9%). Among Stage III patients (<i>N</i> = 118), most frequent patterns were chemotherapy plus radiotherapy (44.9%) and chemotherapy only (18.6%); 58.6% of Stage IIIA patients underwent surgery (of these, 32.4% also received chemotherapy and radiotherapy).</p><p><strong>Conclusion: </strong>Initial strategy was aligned with contemporary at that time European guidelines, setting a benchmark for understanding the future uptake of new therapies.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"447-462"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812321/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947430","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2024-11-29DOI: 10.1080/14796694.2024.2425568
Arvind Dasari, Sara Lonardi, Brian MacLeod, Suzanne McPeak, Josep Tabernero, Cathy Eng
{"title":"Comparing fruquintinib with placebo for treating patients with previously treated metastatic colorectal cancer: a plain language summary of the FRESCO-2 study.","authors":"Arvind Dasari, Sara Lonardi, Brian MacLeod, Suzanne McPeak, Josep Tabernero, Cathy Eng","doi":"10.1080/14796694.2024.2425568","DOIUrl":"10.1080/14796694.2024.2425568","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"281-292"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792833/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142754968","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2024-12-29DOI: 10.1080/14796694.2024.2447813
Li You, Min Wang, Xuexue Liu, Miao Song, Jiahong Zhou, Jia Feng, Jinbo Liu
{"title":"DRP1: shedding light on the complex nexus of mitochondrial fission and breast cancer.","authors":"Li You, Min Wang, Xuexue Liu, Miao Song, Jiahong Zhou, Jia Feng, Jinbo Liu","doi":"10.1080/14796694.2024.2447813","DOIUrl":"10.1080/14796694.2024.2447813","url":null,"abstract":"<p><p>Breast cancer (BC) is a global women's health concern, with ongoing research to address diagnostic and treatment challenges. Understanding the developmental mechanisms is vital for improved clinical prevention and treatment strategies. Mitochondria, undergo dynamic processes like fission and fusion, regulated by proteins like Dynamic-related protein 1 (DRP1). DRP1 plays a key role in mitochondrial fission, a process associated with BC development. This study aims to explore the impact of DRP1 on BC growth, assessing its potential as a therapeutic target. The findings could contribute to a better understanding of mitochondria-related molecular mechanisms in BC development and guide the identification of clinical drug targets.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"593-603"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845117/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143398907","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2024-12-12DOI: 10.1080/14796694.2024.2426425
Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore
{"title":"Plain language summary: does enzalutamide treatment with or without leuprolide improve outcomes and affect quality of life in patients with high-risk biochemical recurrence?","authors":"Stephen J Freedland, Martin Gleave, Ugo De Giorgi, Antti Rannikko, Christopher M Pieczonka, Ronald F Tutrone, Balaji Venugopal, Henry H Woo, Miguel Ramirez-Backhaus, Jamal Tarazi, Yiyun Tang, Arijit Ganguli, Gabriel P Haas, Neal D Shore","doi":"10.1080/14796694.2024.2426425","DOIUrl":"10.1080/14796694.2024.2426425","url":null,"abstract":"","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"501-514"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845099/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142817597","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2024-12-16DOI: 10.1080/14796694.2024.2436342
Raquel Aguiar-Ibáñez, Kelly McQuarrie, Sayeli Jayade, Hannah Penton, Laura DiGiovanni, Rutika Raina, Marieke Heisen, Ana Martinez
{"title":"Impact of recurrence on employment, finances, and productivity for early-stage cancer patients and caregivers: US survey.","authors":"Raquel Aguiar-Ibáñez, Kelly McQuarrie, Sayeli Jayade, Hannah Penton, Laura DiGiovanni, Rutika Raina, Marieke Heisen, Ana Martinez","doi":"10.1080/14796694.2024.2436342","DOIUrl":"10.1080/14796694.2024.2436342","url":null,"abstract":"<p><strong>Background: </strong>Following an early-stage cancer diagnosis, recurrences can occur. To quantify financial impacts of a first recurrence, we surveyed patients and caregivers.</p><p><strong>Methods: </strong>The survey was self-administered online to patients (<i>N</i> = 202) with early-stage bladder, gastric, head and neck, melanoma, non-small cell lung, renal cell, and triple-negative breast cancers that recurred and caregivers (<i>N</i> = 100) of such patients. Work productivity and financial impacts were explored.</p><p><strong>Results: </strong>Negative impacts on work productivity, employment, finances, and healthcare resource use were identified, with significant differences seen across cancer types, between locoregional and distant/metastatic recurrences, and from pre-recurrence to post-recurrence.</p><p><strong>Conclusions: </strong>The financial burden to patients, caregivers, healthcare systems, and society following early-stage cancer recurrence is substantial. Treatments that decrease recurrences can reduce this burden.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"349-365"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11792841/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142828176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"A simplified scoring system for predicting treatment response in limited-stage small-cell lung cancer (EAST score).","authors":"Yu Ito, Yoshitaka Zenke, Tetsuya Sakai, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Shigeki Umemura, Shingo Matsumoto, Kiyotaka Yoh, Masaki Nakamura, Hidehiro Hojo, Takehiro Izumo, Koichi Goto","doi":"10.1080/14796694.2024.2444858","DOIUrl":"10.1080/14796694.2024.2444858","url":null,"abstract":"<p><strong>Aims: </strong>This study aimed at developing a scoring system (EAST score) to predict recurrence after chemoradiotherapy in limited-stage small-cell lung cancer (LS-SCLC).</p><p><strong>Patients & methods: </strong>Treatment-naïve LS-SCLC patients receiving concurrent chemoradiotherapy (CCRT) (<i>N</i> = 234) or sequential chemoradiotherapy (<i>N</i> = 53) were retrospectively reviewed. Using data from CCRT population, clinical and radiological variables associated with disease progression were identified. Selected variables were assigned numerical scores based on their estimated hazard ratios (HRs), and the EAST score was established.</p><p><strong>Results: </strong>EAST score incorporated N3 disease and serum biomarkers (lactate dehydrogenase, pro-gastrin-releasing peptide, and cytokeratin-19 fragment). In the CCRT population, progression-free survival (PFS) was significantly shorter in the high-risk group (EAST score ≥ 2) than the low-risk group (EAST score ≤ 1) (median, 9.4 months vs. 20.6 months; HR [95% confidence interval (CI)], 2.09 [1.50-2.91]). As for the model performance, the 1- and 2-year area under the curve values for PFS were 0.68 and 0.65, respectively. Overall survival was also shorter in the high-risk group (HR [95% CI], 1.49 [1.02-2.16]). Similar trends were observed in the sequential chemoradiotherapy population (HR for PFS [95% CI], 2.43 [1.07-5.53]).</p><p><strong>Conclusions: </strong>EAST score effectively predicts recurrence risk in LS-SCLC, demonstrating the necessity for developing new treatment strategies for high-risk patients.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"473-481"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812385/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142903020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2025-01-26DOI: 10.1080/14796694.2025.2455929
Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig
{"title":"Evaluating patients on CDK-4/6 inhibitor treatment for differences in treatment according to demographic variables.","authors":"Sneha Rajendran, Marina Petruzzi, Dianxu Ren, Catherine Bender, Adam Brufsky, Margaret Q Rosenzweig","doi":"10.1080/14796694.2025.2455929","DOIUrl":"10.1080/14796694.2025.2455929","url":null,"abstract":"<p><strong>Background: </strong>The accessibility and outcomes of cyclin-dependent kinase 4 and 6 inhibitors (CDKi) in metastatic breast cancer (MBC) according to demographic factors are unknown.</p><p><strong>Research design and methods: </strong>Retrospective review of patients with ER+ MBC prescribed first-line CDKi therapy from January 2015 through December 2022. Abstraction included time from CDKi prescription to drug initiation (TTI), time from CDKi initiation to progression (TTP), time from CDKi initiation to death or 6/30/2022, and variables (age, race, partner status, insurance type, BMI, number of comorbidities). Descriptive, comparative, and correlational statistics are used.</p><p><strong>Results: </strong><i>N</i> = 173 patients. No significant demographic differences in TTI or TTP. In the multivariate model TTI to death, patients with Medicaid insurance had significantly shorter overall survival than patients with private insurance.</p><p><strong>Conclusions: </strong>Medicaid insurance is associated with worse outcomes of MBC therapy, not attributed to TTI delay. Personalization of support may be helpful.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"565-568"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845102/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143045789","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Future oncologyPub Date : 2025-02-01Epub Date: 2025-01-09DOI: 10.1080/14796694.2025.2450215
Bobak F Khalili, Tobias Walbert, Craig Horbinski, Karan Dixit, Kapil Gururangan, Helen Thio, Matthew C Tate, Roger Stupp, Rimas V Lukas, Jessica W Templer
{"title":"Levetiracetam and valproic acid in glioma: antiseizure and potential antineoplastic effects.","authors":"Bobak F Khalili, Tobias Walbert, Craig Horbinski, Karan Dixit, Kapil Gururangan, Helen Thio, Matthew C Tate, Roger Stupp, Rimas V Lukas, Jessica W Templer","doi":"10.1080/14796694.2025.2450215","DOIUrl":"10.1080/14796694.2025.2450215","url":null,"abstract":"<p><p>Seizures are a frequent complication in glioma. Incidence of brain tumor-related epilepsy (BTRE) in high-grade glioma (HGG) is an estimated > 25% and in low-grade glioma (LGG) is approximately 72%. Two first-line antiseizure medications (ASMs) for BTRE include levetiracetam (LEV) and valproic acid (VPA). Use of VPA has decreased because of a broader side effect profile, potential interaction with chemotherapeutic drugs, and availability of newer generation agents. In refractory BTRE, LEV and VPA may be prescribed together to enhance seizure control. VPA and LEV have gained attention for their purported antineoplastic effects and synergistic role with temozolomide. VPA is suggested to modulate anticancer activity <i>in vitro</i> through multiple mechanisms. In addition, retrospective studies indicate increased overall survival in patients with epileptogenic HGGs who are managed with LEV or VPA rather than other ASMs. However, these studies have numerous limitations. It is also reported that patients with glioma and a seizure history have a longer survival. This extended survival, if one exists, may be only observed in certain gliomas with corresponding patient characteristics. We provide a brief overview of the management of BTRE, VPA and LEV as anticonvulsants and antineoplastics, and the factors that may be associated with survival in epileptogenic glioma.</p>","PeriodicalId":12672,"journal":{"name":"Future oncology","volume":" ","pages":"483-491"},"PeriodicalIF":3.0,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11812422/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142947193","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
